Publications and Presentations

Category:

Muya et al - Long-acting potential of suprachoroidally delivered BCX4161, a selective plasma kallikrein inhibitor, for diabetic macular edema
Click to View
Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study
Click to View
Ip - Suprachoroidal CLS-TA Plus Aflibercept Compared with Aflibercept Monotherapy for DME: Analysis of OCT Biomarkers in the Randomized Phase 2 TYBEE Trial
Click to View
Ip - Suprachoroidal CLS-TA Plus Aflibercept Compared with Aflibercept Monotherapy for DME: Selected Secondary Results of the Randomized Phase 2 TYBEE Trial
Click to view
Ip - Suprachoroidal CLS-TA Plus Aflibercept Compared with Aflibercept Monotherapy for DME: Primary and Selected Secondary Results of the Randomized Phase 2 TYBEE Trial
Click to view
Wykoff - Suprachoroidal CLS-TA Plus Aflibercept Compared to Aflibercept Monotherapy for DME: Results of the Randomized Phase 2 TYBEE Trial
Click to view
Charles C. Wykoff - Suprachoroidal Triamcinolone for Diabetic Macular Edema: The HULK Trial
Click to View
Shaun I. R. Lampen - Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema
Click to View
Wykoff, C., Khurana, R. - Suprachoroidal Triamcinolone Acetonide with & without Intravitreal Aflibercept for DME: Results of the 6 Month Prospective Phase 1/2 Hulk trial
Click to view
Taraborelli D, Burke B, Noronha G. Ocular Tolerability and Toxicokinetics of Suprachoroidally Administered CLS-TA, Triamcinolone Acetonide Injectable Suspension, in Combination with Intravitreal Eylea® in Rabbits. ARVO Meeting Abstracts 2016; 296-B0329.
Click to view

As a courtesy to our stakeholders, Clearside Biomedical, Inc. lists posters and presentations delivered on, or related to our programs at various medical meetings and in various publications. Some of these materials may be authored by individuals outside the Company with or without funding from Clearside. Please note that the studies, data, opinions, and other disclosures made by these individuals may not fully reflect the status of the Clearside programs. Clearside Biomedical does not by its reference above or distribution necessarily imply its endorsement of or concurrence with such information, conclusions, or recommendations.